Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.66 |
| ▸ | MTOR | P42345 | 19/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL752440 | 0.78 | PIK3CA (0.70) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL757760 | 0.77 | PIK3CA (0.43) | PIK3CAMTORPIK3CBPIK3CD | |
| SCHEMBL754305 | 0.76 | PIK3CA (0.60) | PIK3CAMTORALDH1A1SMN1; SMN2PIK3CB | |
| Trifluoroacetic Acid SCHEMBL751693 | 0.73 | PIK3CA (0.62) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL751843 | 0.69 | PIK3CA (0.43) | PIK3CAMTORALDH1A1SMN1; SMN2PIK3CB | |
| SCHEMBL755037 | 0.68 | PIK3CA (0.69) | PIK3CAMTORPIK3CB | |
| SCHEMBL755349 | 0.65 | PIK3CA (0.42) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL11165037 | 0.65 | PIM1 (0.51) | PIK3CAMTOR | |
| Hydrazine SCHEMBL16161683 | 0.65 | PIK3CA (0.46) | PIK3CAMTORPIK3CB | |
| SCHEMBL4036138 | 0.64 | SMN1; SMN2 (0.65) | PIK3CAMTORALDH1A1SMN1; SMN2PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | PIK3CA 1/4885MTOR 21/4885ALDH1A1 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.